Scilex announces market research results on unmet needs treating acute migraine

Scilex Holding announced that the key product attributes of ELYXYB meet the high unmet needs of clinicians treating patients with acute migraine, with and without aura, in adults, based on the results from a recent market research study. A recent market research study of Neurologists, Headache Specialists and Primary Care Physicians revealed that 93% of clinicians treating migraine have moderate to extremely high unmet needs for alternatives to triptan therapy. Clinicians stated their desire for fast and safe alternatives for two large pools of acute migraine patients – those who have an insufficient response to triptan therapy, and those who have contraindications to triptan use. ELYXYB’s product profile mapped with a high degree of certainty to these stated unmet needs. In clinical studies, patients treated with ELYXYB demonstrated pain relief in as little as 15 minutes, and significant pain relief compared to placebo within 45 minutes in nearly 50% of patients. Approximately 34% of patients were pain free at two hours.3 Notably, these data are well differentiated from two other new oral migraine medications of a different class, calcitonin gene-related peptide receptor antagonists. Recent data from a post hoc analysis presented at the Brain Week Conference in Las Vegas showcased that ELYXYB had higher pain freedom rates from 60 minutes through 3 hours post-dose compared to ubrogepant 100 mg and rimegepant 75 mg.4 As a low-dose COX-2 inhibitor, ELYXYB was safe and well-tolerated in large Phase III clinical studies of 1,253 patients. The most common adverse reaction was dysgeusia. Unlike triptans, ELYXYB is not contraindicated in patients with cardiovascular conditions.